175 related articles for article (PubMed ID: 34940623)
1. Perspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition.
Ruiz FX; Parés X; Farrés J
Metabolites; 2021 Dec; 11(12):. PubMed ID: 34940623
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
3. IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors.
Cousido-Siah A; Ruiz FX; Fanfrlík J; Giménez-Dejoz J; Mitschler A; Kamlar M; Veselý J; Ajani H; Parés X; Farrés J; Hobza P; Podjarny AD
ACS Chem Biol; 2016 Oct; 11(10):2693-2705. PubMed ID: 27359042
[TBL] [Abstract][Full Text] [Related]
4. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008.
Ruiz FX; Crespo I; Álvarez S; Porté S; Giménez-Dejoz J; Cousido-Siah A; Mitschler A; de Lera ÁR; Parés X; Podjarny A; Farrés J
Chem Biol Interact; 2017 Oct; 276():174-181. PubMed ID: 28161411
[TBL] [Abstract][Full Text] [Related]
6. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Cousido-Siah A; Ruiz FX; Mitschler A; Porté S; de Lera ÁR; Martín MJ; Manzanaro S; de la Fuente JA; Terwesten F; Betz M; Klebe G; Farrés J; Parés X; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):889-903. PubMed ID: 24598757
[TBL] [Abstract][Full Text] [Related]
8. Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Matsunaga T; Wada Y; Endo S; Soda M; El-Kabbani O; Hara A
Front Pharmacol; 2012; 3():5. PubMed ID: 22319498
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
11. Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10.
Ruiz FX; Cousido-Siah A; Porté S; Domínguez M; Crespo I; Rechlin C; Mitschler A; de Lera ÁR; Martín MJ; de la Fuente JÁ; Klebe G; Parés X; Farrés J; Podjarny A
ChemMedChem; 2015 Dec; 10(12):1989-2003. PubMed ID: 26549844
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
[TBL] [Abstract][Full Text] [Related]
13. Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase.
Giménez-Dejoz J; Kolář MH; Ruiz FX; Crespo I; Cousido-Siah A; Podjarny A; Barski OA; Fanfrlík J; Parés X; Farrés J; Porté S
PLoS One; 2015; 10(7):e0134506. PubMed ID: 26222439
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Endo S; Xia S; Suyama M; Morikawa Y; Oguri H; Hu D; Ao Y; Takahara S; Horino Y; Hayakawa Y; Watanabe Y; Gouda H; Hara A; Kuwata K; Toyooka N; Matsunaga T; Ikari A
J Med Chem; 2017 Oct; 60(20):8441-8455. PubMed ID: 28976752
[TBL] [Abstract][Full Text] [Related]
16. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J
Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Endo S; Matsunaga T; Soda M; Tajima K; Zhao HT; El-Kabbani O; Hara A
Biol Pharm Bull; 2010; 33(5):886-90. PubMed ID: 20460771
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
19. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]